EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, SLDB: Solid Biosciences Inc

07 Nov 25 15:59
LAST:

4.065

CHANGE:
 0.16		OPEN:
4.210		HIGH:
4.310		ASK:
0.000		VOLUME:
703.7K
CHG(%):
3.68		PREV:
4.215		LOW:
3.790		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 254.1104.2103.7904.060965.7K
06 Nov 253.9404.2203.9404.2151.16M
05 Nov 254.5104.5103.9103.9301.74M
04 Nov 254.7104.8003.9304.4103.02M
03 Nov 255.3505.4805.0905.2001.74M
31 Oct 255.3605.5505.2105.390801.4K
30 Oct 255.4805.6385.2905.310771.1K
29 Oct 255.8805.8805.4605.490929.8K
28 Oct 255.8606.0255.7405.920682.6K
27 Oct 255.7806.0905.7005.900627.1K

COMPANY PROFILE

Name:Solid Biosciences Inc
About:Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:500 Rutherford Avenue, Charlestown, MA, United States, 02129
Website:https://www.solidbio.com
CUSIP:83422E105
CIK:0001707502
ISIN:US83422E2046
FIGI:BBG00JN4FXG8

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:0.15 
Forward P/E:-1.96 
PEG Ratio:0.00 
Price to Sales:3.65 
Price to Book:1.62 
Return on Assets:-0.36 
Return on Equity:-0.68 
EPS Ratio:-2.79 
Shares:77.87M 
Market Cap:316.54M 

TECHNICAL INDICATORS

MA5:4.367.3%
MA10:4.9822.6%
MA20:5.4734.5%
MA50:5.5636.9%
MA100:5.6939.9%
MA200:4.7917.9%
STO9:6.21 
STO14:5.60 
RSI14:21.13 
WPR14:-93.75 
MTM14:-1.95
ROC14:-0.32 
ATR:0.44 
Week High:5.5536.5%
Week Low:3.797.3%
Month High:6.7967.0%
Month Low:3.7917.9%
Year High:7.3781.3%
Year Low:2.4168.7%
Volatility:42.59 

RECENT SPLITS

Date Ratio
28 Oct 20221-15